A Study to Assess Adverse Events and Change in Disease Activity in Participants 12 Years of Age or Older With Locally Advanced or Metastatic Solid Tumors That Harbor MET Amplification Receiving Intravenously Infused Telisotuzumab Adizutecan

PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

125

Participants

Timeline

Start Date

November 25, 2025

Primary Completion Date

December 31, 2030

Study Completion Date

December 31, 2030

Conditions

Solid Tumors Harboring MET Amplification

Interventions

DRUG

Telisotuzumab Adizutecan

Intravenous (IV) Infusion